Very recently it has been shown that CXCR4 inhibitor AMD3100 decreased desmoplasia, immunosuppression and increased T cells infiltration into tumors, and thereby enhanced the efficacy of immune checkpoint inhibition in a pre-clinical murine model of breast cancer (178). This evidence concerns the gene CXCR4 and breast cancer.